Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | 37 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen | |
17.09. | Isofol Medical AB: Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin | 272 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 17, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product... ► Artikel lesen | |
21.08. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2024 | 138 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 21, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2024 is now available, in Swedish, on the... ► Artikel lesen | |
ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
30.07. | Isofol Medical AB: Isofol appoints Magdalena Hagman as new Chief Financial Officer | 191 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 30, 2024 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive... ► Artikel lesen | |
16.07. | Isofol Medical AB: Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin | 266 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies that support the dose-response relationship for arfolitixorin.... ► Artikel lesen | |
08.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-March 2024 | 396 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 8, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-March 2024 is now available, in Swedish, on the... ► Artikel lesen | |
20.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2023 | 213 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 20, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2023 is now available on the company's... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,600 | +0,41 % | MÄRKTE EUROPA/Fest - Evotec haussieren nach Triton-Beteiligungskauf | DJ MÄRKTE EUROPA/Fest - Evotec haussieren nach Triton-Beteiligungskauf
DOW JONES--Europas Börsen halten die Gewinne bis Montagmittag. Gestützt wird die Stimmung von der andauernden Rekordjagd an... ► Artikel lesen | |
MEDIGENE | 1,672 | +3,21 % | PTA-News: Medigene AG: Medigene präsentiert auf der Cell 2024 innovativen Einsatz optimaler T-Zell-Rezeptoren in TCR-gesteuerten Therapien | DJ PTA-News: Medigene AG: Medigene präsentiert auf der Cell 2024 innovativen Einsatz optimaler T-Zell-Rezeptoren in TCR-gesteuerten Therapien
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried... ► Artikel lesen | |
NOVAVAX | 7,259 | -1,26 % | Novavax Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Novavax Inc. (NVAX) released Loss for third quarter that decreased from last year and beat the Street estimates.The company's bottom line totaled -$121.30 million, or... ► Artikel lesen | |
AAP IMPLANTATE | 1,940 | -2,51 % | EQS-NVR: aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: aap Implantate AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach §... ► Artikel lesen | |
OCUGEN | 0,951 | +4,51 % | Ocugen Aktie: Erhoffte Wende bleibt aus | ||
SANGAMO THERAPEUTICS | 2,119 | -8,09 % | Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results.
"This... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 14,800 | -3,01 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress | Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,841 | -2,06 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen | |
CENTOGENE | 0,140 | 0,00 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | ||
ATAI LIFE SCIENCES | 1,248 | -2,00 % | ATAI Life Sciences N.V. - 10-Q, Quarterly Report | ||
NOVOCURE | 17,000 | +0,35 % | Novocure meldet Finanzergebnisse des dritten Quartals 2024 | Quartalsnettoumsatz von 155 Millionen USD, Steigerung von 22 gegenüber dem Vorjahr, mit rekordverdächtigen 4.113 aktiven Patienten in Therapie zum 30. September 2024 FDA genehmigt Optune Lua... ► Artikel lesen | |
BIOMERIEUX | 99,60 | -1,87 % | Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com | The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The... ► Artikel lesen | |
TELIX PHARMACEUTICALS | 14,055 | -1,16 % | AKTIONÄR-Tipp Telix Pharma: Die Lizenz zum Gelddrucken - neues Rekordhoch | Die Aktie des australischen Radiopharma-Spezialisten Telix Pharma hat zum Start in die neue Handelswoche ein frisches Rekordhoch markiert. Kein Wunder, reißt der positive Newsflow des Unternehmens nicht... ► Artikel lesen | |
CYCLACEL | 0,382 | -11,78 % | Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update | BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative... ► Artikel lesen | |
LIQUIDIA | 9,705 | -0,41 % | Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Received tentative approval from the FDA for YUTREPIA (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease... ► Artikel lesen |